The OBR Video Center Features educational videos covering a wide range of oncology specific topics.
Edward Li, PharmD, MPH, BCOP, Associate Professor, University of New England College of Pharmacy, discusses oncology targeting biosimilars that are nearing approval
Published: 04 May 2017
Rana McKay, MD, explains how to differentiate between TKIs available for renal cell cancer patients
Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, describes how to differentiate between the various TKIs available for renal cell cancer (RCC) patients
Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, describes how to differentiate between the various ...
Rana McKay, MD, on next steps when treating mRCC patients who receive I-O in the front line space
Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, considers how to treat patients with metastatic renal cell carcinoma (mRCC) who may be treated with combination I-O in the front line setting
Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, considers how to treat patients with metastatic ...
William Oh, MD, discusses the evolving treatment landscape for patients with nmCRPC
Dr. Oh, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, elaborates on the scope of unmet need for patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and how the treatment landscape is evolving
Dr. Oh, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, elaborates on the scope of unmet need for ...
Rana McKay, MD, offers impressions of the TIVO-3 study in highly refractory advanced RCC patients
Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, shares thoughts on the outcomes from the TIVO-3 study investigating tivozanib in highly refractory advanced renal cell carcinoma (RCC)
Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, shares thoughts on the outcomes from the ...
William Oh, MD, tells us how PSA is valuable as a biomarker in the treatment of prostate cancer
Dr. Oh, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, considers how prostate-specific antigen (PSA) is most valuable as a biomarker in the treatment of prostate cancer
Dr. Oh, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, considers how prostate-specific antigen (PSA) is most valuable ...
Rana McKay, MD, on recent data examining atezolizumab and bevacizumab in nccRCC & sccRCC
Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, offers opinion on whether the results of a GU 2019 Phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (sccRCC) are practice changing
Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, offers opinion on whether the results of ...
William Oh, MD, discusses recent data examining LuPSMA in men with mCRPC
Dr. Oh, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, shares outcomes of the study presented at the 2019 Genitourinary Cancers Symposium using a tumor-specific radioligand - LuPSMA – in men with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on standard therapies
Dr. Oh, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, shares outcomes of the study presented at the ...
Rana McKay, MD, considers the implications of CHECKMATE 214 & KEYNOTE-426 presented at GU 2019
Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, on whether the results of KEYNOTE-426 and CHECKMATE 214 influence how we treat intermediate/poor risk renal cell cancer (RCC) patients versus those that are favorable risk in the first line setting
Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, on whether the results of KEYNOTE-426 and ...
William Oh, MD, regarding data on racial differences in response to novel prostate cancer therapies
Dr. Oh, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, summarizes the large retrospective trial presented the 2019 Genitourinary Cancers Symposium demonstrating that African-American men may respond well to newer prostate cancer therapies
Dr. Oh, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, summarizes the large retrospective trial presented the 2019 ...
Rana McKay, MD, elaborates on the outcomes of the KEYNOTE 426 Phase III study in mRCC
Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, shares outcomes of the KEYNOTE 426 Phase III study investigating pembrolizumab combined with axitinib versus standard of care sunitinib as first line therapy for metastatic renal cell carcinoma (mRCC)
Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, shares outcomes of the KEYNOTE 426 Phase ...
William Oh, MD, discusses the evolving treatment landscape for patients with nmCRPC
Dr. Oh, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, elaborates on the scope of unmet need for patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and how the treatment landscape is evolving
Rana McKay, MD, on next steps when treating mRCC patients who receive I-O in the front line space
Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, considers how to treat patients with metastatic renal cell carcinoma (mRCC) who may be treated with combination I-O in the front line setting
Rana McKay, MD, explains how to differentiate between TKIs available for renal cell cancer patients
Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, describes how to differentiate between the various TKIs available for renal cell cancer (RCC) patients
William Oh, MD, discusses recent data examining LuPSMA in men with mCRPC
Dr. Oh, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, shares outcomes of the study presented at the 2019 Genitourinary Cancers Symposium using a tumor-specific radioligand - LuPSMA – in men with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on standard therapies
Rana McKay, MD, on recent data examining atezolizumab and bevacizumab in nccRCC & sccRCC
Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, offers opinion on whether the results of a GU 2019 Phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (sccRCC) are practice changing
William Oh, MD, tells us how PSA is valuable as a biomarker in the treatment of prostate cancer
Dr. Oh, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, considers how prostate-specific antigen (PSA) is most valuable as a biomarker in the treatment of prostate cancer
Rana McKay, MD, offers impressions of the TIVO-3 study in highly refractory advanced RCC patients
Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, shares thoughts on the outcomes from the TIVO-3 study investigating tivozanib in highly refractory advanced renal cell carcinoma (RCC)
Yair Lotan, MD, on the challenges using biomarkers for treatment selection in bladder cancer
Dr. Lotan, Professor of Urology, Chief of Urologic Oncology, University of Texas Southwestern Medical Center, discusses some of the present challenges with using biomarkers for treatment selection in muscle-invasive and non-muscle-invasive bladder cancer
Andrew Armstrong, MD, presents an overview of the ARCHES trial in mHSPC
Dr. Armstrong, Professor of Medicine, Duke Cancer Institute, Center for Prostate and Urologic Cancers, shares results from the ARCHES trial presented at the 2019 Genitourinary Cancers Symposium investigating androgen deprivation therapy (ADT) with enzalutamide or placebo in metastatic hormone-sensitive prostate cancer (mHSPC)
Mark T. Fleming, MD, regarding the implications of the CHECKMATE 650 study presented at GU 2019
Dr. Fleming, Medical Oncology, Medical Director, Genitourinary Program, US Oncology, Virginia Oncology Associates, tells us about the results of CHECKMATE 650 and the potential to use immune checkpoint inhibitor combinations to treat metastatic castration-resistant prostate cancer (mCRPC)
Michael Atkins, MD, regarding the KEYNOTE 426 Phase III trial in metastatic renal cell carcinoma
Dr. Atkins, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical Center, shares thoughts on the KEYNOTE 426 Phase III study investigating pembrolizumab combined with axitinib versus standard of care sunitinib as first line therapy for metastatic renal cell carcinoma (mRCC)
Yair Lotan, MD, shares outcomes of KEYNOTE 057 in high-risk non-muscle-invasive bladder cancer
Dr. Lotan, Professor of Urology, Chief of Urologic Oncology, University of Texas Southwestern Medical Center, elaborates on outcomes from the KEYNOTE 057 trial investigating pembrolizumab in patients with high-risk non-muscle-invasive bladder cancer unresponsive to BCG
Andrew Armstrong, MD, discusses the Phase 2 STREAM study in pre-metastatic prostate cancer
Dr. Armstrong, Professor of Medicine, Duke Cancer Institute, Center for Prostate and Urologic Cancers, regarding the outcomes of the Phase 2 STREAM study investigating enzalutamide plus salvage radiation plus androgen deprivation therapy (ADT) in men with pre-metastatic prostate cancer
Yair Lotan, MD, considers the role of checkpoint inhibitors in bladder cancer
Dr. Lotan, Professor of Urology, Chief of Urologic Oncology, University of Texas Southwestern Medical Center, explains how checkpoint inhibition is being incorporated into muscle-invasive and non-muscle-invasive bladder cancer treatment algorithms and whether it appears to combine well with chemotherapy
Michael Atkins, MD, offers opinion on IO-TKI combinations in renal cell cancer
Dr. Atkins, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical Center, discusses combining checkpoint inhibition or any I-O with TKIs in renal cell cancer patients
Rana McKay, MD, elaborates on the outcomes of the KEYNOTE 426 Phase III study in mRCC
Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, shares outcomes of the KEYNOTE 426 Phase III study investigating pembrolizumab combined with axitinib versus standard of care sunitinib as first line therapy for metastatic renal cell carcinoma (mRCC)
Andrew Armstrong, MD, offers opinion on androgen receptor inhibitors
Dr. Armstrong, Professor of Medicine, Duke Cancer Institute, Center for Prostate and Urologic Cancers, elaborates on his experience with androgen receptor inhibitors and how they may impact bone scans
William Oh, MD, regarding data on racial differences in response to novel prostate cancer therapies
Dr. Oh, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, summarizes the large retrospective trial presented the 2019 Genitourinary Cancers Symposium demonstrating that African-American men may respond well to newer prostate cancer therapies
Mark T. Fleming, MD, on the ARCHES trial in metastatic hormone-sensitive prostate cancer
Dr. Fleming, Medical Oncology, Medical Director, Genitourinary Program, US Oncology, Virginia Oncology Associates, regarding outcomes from the ARCHES trial presented at the 2019 Genitourinary Cancers Symposium investigating androgen deprivation therapy (ADT) with enzalutamide or placebo in metastatic hormone-sensitive prostate cancer (mHSPC)
Rana McKay, MD, considers the implications of CHECKMATE 214 & KEYNOTE-426 presented at GU 2019
Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, on whether the results of KEYNOTE-426 and CHECKMATE 214 influence how we treat intermediate/poor risk renal cell cancer (RCC) patients versus those that are favorable risk in the first line setting
© Caribou Publishing. All rights reserved. Reproduction in whole or in part is prohibited.